TrialHuman vaccines & immunotherapeutics2026

Safety and immunogenicity of a COVID-19-Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase 1/2 clinical trial.

Vivek Shinde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.